Patent intelligence · US
US 12213996
Methods of treating optic nerve diseases using neural progenitor cell growth factors
Methods of treating optic nerve diseases using neural progenitor cell growth factors
Patent details — US 12213996
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 4, 2025
- Expiration
- Jan 30, 2045
- Applicant
- REGENERATIVE RESEARCH FOUNDATION
- Claims
- 17
- CPC classes
- A61K, A61K35/30, A61K38/18, A61K38/1825
Quick answer
US 12213996 (Methods of treating optic nerve diseases using neural progenitor cell growth factors) is held by REGENERATIVE RESEARCH FOUNDATION. Status: granted. Granted Feb 4, 2025. Expires Jan 30, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENERATIVE RESEARCH FOUNDATION
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K35/30, A61K38/18, A61K38/1825, A61K38/1841, A61K38/185
More from REGENERATIVE RESEARCH FOUNDATION
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 12213996?
US 12213996 (Methods of treating optic nerve diseases using neural progenitor cell growth factors) is held by REGENERATIVE RESEARCH FOUNDATION. Status: granted. Granted Feb 4, 2025. Expires Jan 30, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12213996?
REGENERATIVE RESEARCH FOUNDATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 12213996 expire?
Our index shows an expiration date of Jan 30, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.